Pamplona completes take-private acquisition of Parexel

Pamplona Capital has closed its take-private buyout of Parexel International Corp for $88.10 per share. The Parexel stock has stopped trading on the NASDAQ. As a result of the deal, Josef von Rickenbach will remain CEO of Parexel while Dr. Jeremy Gelber, a partner at Pamplona, will serve on Parexel's board of directors. Massachusetts-based Parexel is a global biopharmaceutical services company.

DealsNorth AmericaUSBriefs